Report cover image

Diabetic Retinopathy (DR)

Publisher Reach Market Research
Published Jun 01, 2021
Length 20 Pages
SKU # RMR19136492

Description

MarketVue®: Diabetic Retinopathy

The MarketVue®: Diabetic Retinopathy market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Diabetic Retinopathy report is supported by 3 qualitative interviews with key opinion leaders, a quantitative survey with 19 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Regeneron Pharmaceuticals
• Novartis
• Hoffmann-La Roche
• Adverum Biotechnologies
• Regenexbio
• Oxurion
• Graybug Vision
• Kubota Vision
• Opthea

Key drugs mentioned:
• Aflibercept (Eylea)
• Ranibizumab (Lucentis)
• Bevacizumab (Avastin)
• Faricimab (Vabysmo)
• Ranibizumab port delivery system (Susvimo)
• Brolucizumab (Beovu)
• RGX-314
• ADVM-022
• THR-149
• GB-102
• Emixustat
• OPT-302
• THR-687

Please note: the online download version of this report is for a global site license.

Table of Contents

20 Pages
1. DISEASE OVERVIEW
Blood vessel impairment underlies vision impairment in diabetic retinopathy
Hallmarks of diabetic retinopathy
Figure 1.1. Stages of diabetic retinopathy
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. Diagnosed prevalent cases of diabetic retinopathy by region
Table 2.1. Diagnosed prevalent and drug-treated diabetic retinopathy patients in the US and EU5
Figure 2.2. Segmentation of total prevalent cases of diabetic retinopathy by severity
3. CURRENT TREATMENT
Treatment goals
Figure 3.1. Treatment goals for diabetic retinopathy
Standard of care
Figure 3.2. Patient share of anti-VEGF treatment
Table 3.1. Current anti-VEGF usage by retinal specialists
Treating physicians
Referring physicians
Figure 3.3. Diagnosis and treatment flow for diabetic retinopathy
Must-know treatment dynamics for diabetic retinopathy
Barriers to patient care
Figure 3.4. Percent of retina specialists rating factor as impactful
Figure 3.5. Potential timeline of diabetic retinopathy market evolution
Is earlier treatment with current therapies on the horizon? Not so fast.
Figure 3.6. Retina specialist experimentation with anti-VEGF for NPDR
4. UNMET NEED
Treatment-related unmet needs
Figure 4.1. Top unmet needs in diabetic retinopathy
Figure 4.2. Percentage of retina specialists ranking unmet need in their top two
Unmet need by type of diabetic retinopathy
Figure 4.3. Percentage of retina specialists citing extremely high unmet need by disease type
Early prevention and reversal of disease progression
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Number of emerging therapies addressing unmet needs in diabetic retinopathy
Gene therapy has caught the eye of retinal specialists
Figure 5.2. Percent of retina specialists rating target/approach as promising
Table 5.1. Emerging therapies in clinical development for diabetic retinopathy
Retina specialists’ pipeline knowledge
Figure 5.3. Percent of retina specialists familiar with emerging therapy
6. VALUE & ACCESS
Overview
Table 6.1. Annual cost and sales of anti-VEGF therapies
CMS is the predominant payer for diabetic retinopathy patients
Figure 6.1. Payer mix for diabetic retinopathy
Figure 6.2. Phase III biosimilars on the horizon for Eylea and Lucentis
7. METHODOLOGY
Primary market research methodology
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us